NephroGenex Announces Full Enrollment In New Pyridorin(TM) Clinical Trial - PYR 210
NephroGenex, Inc., a privately held drug development company focusing on kidney disease, announced the completion of patient enrollment in its Phase 2b clinical trial (PYR210) studying the safety and efficacy of its lead drug candidate Pyridorin(TM) (pyridoxamine dihydrochloride) in type 2 diabetic patients with overt diabetic nephropathy. Three hundred and seventeen (317) patients have been [...]